ifosfamide has been researched along with Dysmyelopoietic Syndromes in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Poor-risk solid tumors were treated with four courses of cyclophosphamide (4,200 mg/m2)/ doxorubicin (75 mg/m2), and three courses of ifosfamide (9,000 mg/m2)/etoposide (500 mg/m2)." | 2.69 | High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. ( Bajorin, D; Cheung, NK; Heller, G; Kramer, K; Kushner, BH; Meyers, PA; Polyak, T; Wollner, N, 1998) |
| " Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated." | 1.37 | Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. ( Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M, 2011) |
| "One patient developed a secondary acute myeloid leukemia (s-AML) involving a chromosomal translocation t(11;19)(q23;p13." | 1.33 | Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. ( Boehlke, I; Bokemeyer, C; Hartmann, JT; Kanz, L; Kollmannsberger, C; Kuczyk, M; Metzner, B; Schleicher, J; Schleucher, N; Wierecky, J, 2005) |
| "The interval between diagnosis of Ewing's sarcoma and the diagnosis of the SM was 17-78 months for the four AMLs, 96 months for the MDS and 82-136 months for the three sarcomas." | 1.30 | Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. ( Ahrens, S; Dunst, J; Harms, D; Jürgens, H; Paulussen, M; Rübe, C; Winkelmann, W; Zoubek, A, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scholz, M | 1 |
| Engert, A | 1 |
| Franklin, J | 1 |
| Josting, A | 1 |
| Diehl, V | 1 |
| Hasenclever, D | 1 |
| Loeffler, M | 1 |
| Kawakami, K | 1 |
| Watanabe, Y | 1 |
| Kadowaki, S | 1 |
| Christodoulou, J | 1 |
| Schoch, C | 1 |
| Schnittger, S | 1 |
| Haferlach, T | 1 |
| Wierecky, J | 1 |
| Kollmannsberger, C | 1 |
| Boehlke, I | 1 |
| Kuczyk, M | 1 |
| Schleicher, J | 1 |
| Schleucher, N | 1 |
| Metzner, B | 1 |
| Kanz, L | 1 |
| Hartmann, JT | 1 |
| Bokemeyer, C | 1 |
| Takizawa, A | 1 |
| Miura, T | 1 |
| Fujinami, K | 1 |
| Osada, Y | 1 |
| Tanaka, M | 1 |
| Maruta, I | 1 |
| Kushner, BH | 1 |
| Heller, G | 1 |
| Cheung, NK | 1 |
| Wollner, N | 1 |
| Kramer, K | 1 |
| Bajorin, D | 1 |
| Polyak, T | 1 |
| Meyers, PA | 1 |
| Dunst, J | 1 |
| Ahrens, S | 1 |
| Paulussen, M | 1 |
| Rübe, C | 1 |
| Winkelmann, W | 1 |
| Zoubek, A | 1 |
| Harms, D | 1 |
| Jürgens, H | 1 |
1 trial available for ifosfamide and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dose-Res | 1998 |
6 other studies available for ifosfamide and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine | 2011 |
[Therapy-related acute myelogenous leukemia (AML-M6) with add(11) (q23) and del(20) (q11.2) developing via myelodysplastic syndrome after chemotherapy for malignant lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 11; | 2003 |
Myelodysplastic syndrome (RARS) with +i(12p) abnormality in a patient 10 months after diagnosis and successful treatment of a mediastinal germ cell tumor (MGCT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 12; Cisplatin; Etopo | 2004 |
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Etopo | 2005 |
[A case of therapy-related leukemia/myelodysplastic syndrome following treatment of refractory testicular germ cell tumor].
Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Ci | 2005 |
Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 1998 |